Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetuzumab (IBI311) in Moderate to Severe TAO After Glucocorticoid Treatment
NCT07152366Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of sycume in thyroid associated ophthalmopathy (TAO) (3 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Percentage of participants who were overall treatment responders at 24 weeks, Percentage of participants who were CAS categorical responders at 24 weeks and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
sycume
03
Conditions
thyroid associated ophthalmopathy (TAO)
Beyond the preview
Go deeper on NCT07152366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152366.